Organon & Co. (OGN) Price Prediction 2026–2050

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.

Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis.

Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss.

The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Organon & Co. is a Healthcare stock with a current price of $13.52 and a market cap of $3.55B, ranking 1569 by size among peers. The near-term setup shows a price near the 50-day trend line, with a constructive longer-term trajectory indicated by a series of rising average prices in the forecast.

The multi-year outlook points to strong upside potential, with average prices climbing toward the mid-to-high teens in the late 2020s and well into the 2030s and beyond, accompanied by rising ROIs.

In the near term, the model projects a 2026 average of $13.52, then increasing through 2027 ($16.46) and 2028 ($17.78), extending into 2030 ($26.31). The longer horizon forecasts further upside, with 2031 ($29.27), 2032 ($33.85), 2033 ($37.88), 2034 ($38.09), and 2035 ($42.01) on the path to significantly higher levels by 2040 ($69.59) and 2050 ($135.75). The sentiment shifts from Neutral in 2026 to Bullish from 2027 onward, indicating an overall positive price outlook over the forecast period.

The long-run forecast paints a bullish trajectory across the latter 2020s into the 2030s and beyond. The 2027 average is $16.46, followed by 2028 at $17.78, 2029 at $20.83, and 2030 at $26.31, with a forecasted ROI of 94.6% for 2030. The outlook then extends through 2031 ($29.27), 2032 ($33.85), 2033 ($37.88), 2034 ($38.09), and 2035 ($42.01), each with positive sentiment.

Beyond 2035, the forecast shows continued upside, with 2040 average $69.59 (ROI 414.7%) and 2050 average $135.75 (ROI 904%). The ranges for select years illustrate the potential for higher extremes: 2030 min $20.56 and max $35.84; 2040 min $49.43 and max $106.13; 2050 min $89.90 and max $221.92. These are estimates, not guarantees, and carry inherent uncertainty but point to a bullish longer-term trajectory.